Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig Reeder, M.D.
Mayo Clinic
Principal Investigator - Thomas E. Witzig, MD
Mayo Clinic
Study Chair - Vivek Roy, M.D.
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
- Mayo Clinic Cancer Center
Rochester, Minnesota, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2003
- Primary completion
- 30 Jun 2011
- Completion
- 30 Apr 2012
- Last update posted
- 4 Jul 2012
- Registered enrollment
- 68
- Registry id
- NCT00432458
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.